Add to Calendar 8/26/2020 8:00:00 AM 8/27/2020 5:00:00 PM 2020 State of Possible Conference

Special thanks to our Platinum Sponsor Morgan Stanley

Registered attendees will receive an email with the subject line “Welcome to the State of Possible Conference 2020 - Event Access Link” from

The State of Possible Conference, MassBio's Annual Meeting, will now be hosted virtually on August 26-27, 2020. Featuring interactive networking and a groundbreaking viewer experience, this event will not be your average webinar.  

We will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks®, inspiring and engaging content in the style of a TED Talk.

"It's the Woodstock of Life Sciences, with all-star performers playing their greatest hits all on one stage.” – 2019 State of Possible Conference attendee
If you haven’t attended our State of Possible Conference before, it is the premier east coast life sciences conference. We have some of the brightest names in biotech talking about the issues impacting our industry, covering topics from the realities of precision medicine to advancing new drug targets faster.

To inquire about sponsorship opportunities, contact Laura Rudberg.

2020 State of Possible Conference Refund Policy

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
Online Conference, Link will be sent in advance of the event.
Head, Chemical Biology and Therapeutics department at Novartis Institutes for Biomedical Research
John Tallarico is the Head, Chemical Biology and Therapeutics department at Novartis Institutes for Biomedical Research. In this role, John’s mission is focused on the early stages of therapeutic discovery, including target identification, target validation, and moving early discoveries into the drug discovery pipeline. This work covers all therapeutic areas of interest to Novartis. Prior to Novartis, John served as Head of Chemical Technologies at the Harvard Institute for Chemistry and Cell Biology where he was an Instructor in the Department of Cell Biology, Harvard Medical School from 2000 to 2004. At that time, John’s research was focused on the nascent field of Chemical Genetics. John received in PhD in Chemistry from Boston College and a B.A. in Chemistry from Miami University.

Brought to you by